Know Cancer

or
forgot password

Use of PET/CT Imaging With 18F-fluoroethylcholine (FEC) in the Evaluation of Patients Treated With Radiotherapy and Temozolomide Following a Diagnosis of Glioblastoma Multiforme


N/A
18 Years
70 Years
Not Enrolling
Both
Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme

Thank you

Trial Information

Use of PET/CT Imaging With 18F-fluoroethylcholine (FEC) in the Evaluation of Patients Treated With Radiotherapy and Temozolomide Following a Diagnosis of Glioblastoma Multiforme

Inclusion Criteria


Inclusion criteria:

- Age between 18 and 70 years of age

- Histological diagnosis of GBM (grade IV astrocytoma based on the World Health
Organization [WHO] classification)

- No previous radiotherapy or chemotherapy

- No history of previous neoplasms

- Inoperable patients (tumour in place, biopsy only)

- KPS ≥ 70

- Adequate hematological, renal and hepatic function

- Absolute neutrophil count ≥ 1,500/mm3

- Platelets ≥ 100,000 per mm3

- Serum creatinine ≤ 1.5 times the upper limit of normal of the laboratory where
it is measured

- Total bilirubin ≤ 1.5 times the upper limit of normal of the laboratory where it
is measured

- Liver enzymes < 3 times the upper limit of normal of the laboratory where they
are measured

- Patients under corticosteroids must have received a stable or decreasing dose in the
14 days preceding randomization

- Consent form signed by the patients

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Principal Investigator

Marie-Andrée Fortin, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Centre Hospitalier de l'Université de Montréal

Authority:

Canada: Health Canada

Study ID:

CE-08-234

NCT ID:

NCT00943462

Start Date:

June 2009

Completion Date:

June 2011

Related Keywords:

  • Astrocytoma, Grade IV
  • Giant Cell Glioblastoma
  • Glioblastoma Multiforme
  • Astrocytoma
  • Glioblastoma

Name

Location